Ovidrel Self-Injection Technique: How to Give Your Trigger Shot Correctly

What Ovidrel Is and Why the Injection Timing Is Non-Negotiable

Ovidrel is a single, precisely timed subcutaneous injection used to trigger final egg maturation during fertility treatment. Missing your injection window, even by two hours, can shift the ovulation timeline and reduce cycle success. Your care team will give you an exact clock time. Treat that time as a medical appointment you cannot reschedule.

Choriogonadotropin alfa is a recombinant form of human chorionic gonadotropin (hCG) produced in Chinese hamster ovary cells. Unlike urinary hCG products derived from pregnant women's urine, Ovidrel is biosynthetically manufactured, which means more consistent batch-to-batch potency and a known, fixed dose of 250 mcg per prefilled syringe.

The drug was approved by the FDA for the induction of final follicular maturation and early luteinization in women who have been appropriately pre-treated with follicle-stimulating hormone (FSH). It is manufactured by EMD Serono and dispensed as a prefilled, single-use subcutaneous syringe.

How Ovidrel Works in Your Body

Ovidrel mimics the natural LH surge that triggers ovulation in a spontaneous cycle. After you inject 250 mcg subcutaneously, choriogonadotropin alfa binds to LH/hCG receptors on granulosa and theca cells in your ovarian follicles. This binding drives oocyte meiotic resumption, cumulus expansion, and follicle rupture within approximately 36 to 42 hours.

In an IVF cycle, your retrieval is scheduled 34 to 36 hours after injection, just before spontaneous follicle rupture would otherwise occur. In an IUI or timed-intercourse cycle, ovulation is expected approximately 36 to 40 hours post-injection.

Why Recombinant hCG Differs from Urinary hCG

Urinary hCG products (Pregnyl, Novarel) are measured in international units (IU). The 250 mcg dose of choriogonadotropin alfa delivers an LH-equivalent bioactivity of approximately 6,500 IU of urinary hCG. A 2002 comparative study found equivalent clinical outcomes between the two forms, but Ovidrel's fixed-dose prefilled format eliminates reconstitution errors, which is a meaningful practical advantage when you are injecting at home, possibly at midnight, alone.

Who Uses Ovidrel and at Which Life Stage

Ovidrel is used exclusively during the reproductive years. Your fertility specialist determines whether it is the right trigger for your protocol.

IVF Cycles

In a standard antagonist or long-lupron IVF protocol, Ovidrel (or a similar hCG trigger) is given after follicles have reached a target size of approximately 18 to 20 mm on ultrasound and estradiol levels support adequate follicular cohort maturation. A randomized controlled trial comparing choriogonadotropin alfa to urinary hCG found no significant difference in the number of oocytes retrieved or clinical pregnancy rate, confirming that the recombinant version is a reliable substitute.

Women with polycystic ovary syndrome (PCOS) are at higher risk of ovarian hyperstimulation syndrome (OHSS) with any hCG trigger. If you have PCOS and are doing IVF, your team may prefer a GnRH agonist trigger (leuprolide acetate) instead of Ovidrel to reduce OHSS risk. Ask specifically about this if PCOS has been part of your diagnosis.

IUI and Timed-Intercourse Cycles

In ovarian stimulation cycles using clomiphene citrate or low-dose FSH for IUI or timed intercourse, Ovidrel is injected when the lead follicle reaches approximately 18 to 20 mm. Insemination or intercourse is then scheduled 36 hours later, though your clinic may specify 24, 36, or both days.

Women with Unexplained Infertility or Irregular Cycles

If your cycles are irregular due to hypothalamic dysfunction, thyroid disease, or hyperprolactinemia, your underlying condition should be stabilized before any trigger protocol. Ovidrel alone does not address cycle irregularity. It is a downstream tool used only after ovarian stimulation has produced mature follicles.

Step-by-Step: How to Self-Inject Ovidrel

Self-injection is manageable with preparation. Most women give their first Ovidrel injection successfully at home with no nursing support.

What You Need Before You Start

Gather everything before you open the packaging:

• The Ovidrel prefilled syringe (confirm it has been stored correctly)
• One alcohol swab
• A small gauze pad or cotton ball
• A sharps disposal container (a hard-walled, puncture-resistant container)
• A clean, flat, well-lit surface

Do not use the syringe if the solution is cloudy, discolored, or contains visible particles. The solution should be clear and colorless.

Step 1: Check Your Timing and Storage

Pull the syringe from the refrigerator 15 to 20 minutes before injection. Injecting a cold solution can sting more. Ovidrel may be stored at room temperature (up to 77 degrees F / 25 degrees C) for up to 30 days, but refrigeration is preferred until the day of use.

Confirm the time your clinic gave you. If you have a calendar reminder set, double-check it is for the correct AM vs PM designation.

Step 2: Wash Your Hands

Wash with soap and water for 20 seconds. Dry with a clean towel. This step is not optional.

Step 3: Choose and Prepare Your Injection Site

The two recommended sites for subcutaneous injection are:

• Abdomen: At least two inches away from your navel, alternating sides
• Upper thigh: Outer, fleshy portion of the thigh, mid-way between your knee and hip

Avoid areas with bruising, redness, tenderness, or scar tissue. Clean the chosen spot with the alcohol swab using a single outward circular motion. Let it dry for 10 full seconds before injecting. Injecting through wet alcohol stings and can introduce discomfort.

Step 4: Prepare the Syringe

Remove the cap straight off, without twisting, to avoid bending the needle. Do not touch the needle. Do not expel air bubbles unless your clinic has specifically instructed you to; the prefilled syringe is designed to deliver the full 250 mcg dose as packaged, and a small air bubble in a subcutaneous syringe is not medically significant.

Step 5: Inject

Gently pinch a fold of skin with your non-dominant hand. This lifts the subcutaneous fat away from the muscle. Hold the syringe like a pencil in your dominant hand. Insert the needle at a 45 to 90-degree angle, depending on how much subcutaneous tissue you have.

• If you are lean with minimal abdominal fat: use 45 degrees
• If you have more subcutaneous tissue: 90 degrees works well

Push the needle in with a smooth, quick motion. Inject the solution slowly over 3 to 5 seconds by pressing the plunger steadily. Do not pull the plunger back (aspiration is not required or recommended for subcutaneous injections per current clinical guidance).

Step 6: Remove and Dispose

Release the skin pinch. Withdraw the needle at the same angle you inserted it. Press gently with a gauze pad; do not rub, as rubbing disperses the medication unevenly under the skin. Place the entire syringe directly into your sharps container. Cap it only if your local protocol requires it and you can do so safely.

Step 7: Log the Injection

Write down the exact time, the site used, and whether any solution leaked. If more than a few drops visibly leaked out, call your clinic before your retrieval or IUI is scheduled. They may advise a repeat dose or a serum hCG check.

Common Injection Concerns and How to Handle Them

Bruising and Soreness

Subcutaneous injections into the abdomen commonly cause small bruises, especially later in a stimulation cycle when you may have done multiple injections nearby. Rotating sites reduces this. Applying gentle pressure with a cool pack for one to two minutes after injection also helps.

Lump Under the Skin

A small raised area immediately after injection is normal. It means the solution pooled in the subcutaneous tissue and will absorb over 15 to 30 minutes. A lump that persists longer than an hour, becomes warm, or spreads may indicate an injection too close to the skin surface rather than into subcutaneous tissue. Adjust your angle slightly on future injections.

Fear of Needles

This is common and worth taking seriously. Research on women undergoing fertility treatment consistently identifies injection anxiety as a meaningful quality-of-life burden. Strategies that help: having a partner inject while you look away, using ice for 30 seconds before injection to numb the skin, or asking your clinic for a 30-gauge needle if available. Some compounding pharmacies also offer a topical lidocaine cream (EMLA) that can be applied 45 to 60 minutes before injection.

"I Forgot and It Has Been Two Hours"

Call your clinic immediately. Do not inject late on your own without guidance. In many IVF cycles, a two-hour delay shifts the retrieval window and may mean the eggs are either immature or have already ovulated. Your team may recheck follicle status with ultrasound or serum hCG to decide how to proceed.

Pregnancy and Lactation Safety

Ovidrel is contraindicated if you are already pregnant. This is a required warning, stated plainly here: do not inject Ovidrel if a pregnancy has been confirmed. The drug is used to trigger ovulation, not to support an established pregnancy, and exogenous hCG does not replace the hCG produced by a developing embryo in a way that is medically beneficial.

Pregnancy Category X Equivalent

Ovidrel carries a pregnancy category X designation under the older FDA system, meaning it is contraindicated in pregnancy. This designation applies because hCG has known teratogenic potential in animal models at supraphysiologic doses.

A practical note: because Ovidrel is used as a fertility trigger, the scenario of injecting it while pregnant is uncommon in clinical practice. The rare exception would be a woman who becomes pregnant spontaneously in a stimulated cycle before the trigger is given. Any positive home pregnancy test before your scheduled trigger dose should prompt an immediate call to your clinic before you inject.

Ovidrel and Pregnancy Test Interpretation

Ovidrel will cause a false-positive result on a urine pregnancy test for approximately 10 to 14 days after injection. This is because the assay detects hCG, and the injected choriogonadotropin alfa is structurally identical to pregnancy-derived hCG. Testing too early after an hCG trigger is one of the most common sources of emotional distress in fertility treatment. Your clinic will schedule a serum beta-hCG at a specific number of days post-retrieval or post-IUI. Follow that schedule rather than home tests.

Lactation

There are no adequate human studies on choriogonadotropin alfa transfer into breast milk. Women who are lactating and pursuing fertility treatment represent a small but real group, particularly those seeking a second pregnancy postpartum. Because data are absent rather than reassuring, most clinicians advise against using Ovidrel while breastfeeding, and fertility treatment involving ovarian stimulation is generally deferred until weaning is complete or substantially reduced. Discuss timing with your reproductive endocrinologist.

OHSS Risk: What Every Woman Needs to Know Before Injecting

Ovarian hyperstimulation syndrome (OHSS) is the most serious risk associated with hCG trigger. Ovidrel, like all hCG-based triggers, can precipitate OHSS in susceptible women. Mild OHSS causes bloating, pelvic discomfort, and nausea in the days following the trigger. Severe OHSS involves fluid shifts, hemoconcentration, and rarely thromboembolism.

Who Is at Higher Risk

• Women with PCOS
• Women with antral follicle counts above 20 to 25 per ovary
• Women with estradiol above 3,000 to 4,000 pg/mL on trigger day
• Prior cycles with OHSS history
• Women with a low body weight

The American Society for Reproductive Medicine (ASRM) recommends considering a GnRH agonist trigger instead of hCG for women at high risk of OHSS in GnRH antagonist IVF cycles, as it significantly reduces the risk of moderate-to-severe OHSS while preserving oocyte yield. Ask your doctor about your personal OHSS risk profile before every stimulated cycle.

Warning Signs After Injection

Contact your clinic the same day if you develop:

• Rapid weight gain of more than two pounds in 24 hours
• Severe abdominal pain or distension
• Decreased urination
• Nausea or vomiting that prevents eating or drinking
• Shortness of breath

Do not wait to see if symptoms resolve on their own.

Who This Is Right for and Who Should Pause

The table below synthesizes clinical criteria across ASRM guidance and fertility trial data to help you understand where Ovidrel fits, framed by life stage and condition.

| Clinical Situation | Ovidrel Appropriate? | Notes | |---|---|---| | Reproductive years, IVF antagonist protocol, normal OHSS risk | Yes | Standard first-line trigger | | Reproductive years, PCOS, high OHSS risk, IVF | Often no | GnRH agonist trigger preferred; discuss with REI | | IUI cycle, clomiphene or low-dose FSH | Yes | Standard trigger when lead follicle is ready | | Timed intercourse with single dominant follicle | Yes | 36-hour timing applies | | Pregnancy already confirmed | No (contraindicated) | Do not inject | | Breastfeeding, pursuing fertility treatment | Use with caution | Limited data; discuss deferral with REI | | Luteal phase deficiency with prior hCG supplementation | Not the same indication | Luteal hCG support uses different dosing regimens | | Perimenopausal women, low ovarian reserve | Sometimes | Used if stimulation produces viable follicles; outcomes differ significantly from younger cohorts |

Sex-Specific Pharmacokinetics: How Your Body Processes Ovidrel

The pharmacokinetics of subcutaneous choriogonadotropin alfa have been studied almost exclusively in women, which is appropriate because the drug has no clinical application in male fertility in this form and dose. Following a single 250 mcg subcutaneous injection in women undergoing pituitary downregulation, peak serum hCG concentrations (Cmax) of approximately 121 mIU/mL are reached at approximately 24 hours (Tmax). The terminal half-life is approximately 29 hours.

This relatively long half-life is why a urine pregnancy test remains positive for 10 to 14 days after the injection. It is also why the trigger works: sustained receptor occupancy drives the entire cascade of oocyte maturation, cumulus expansion, and follicle rupture over the 34 to 36-hour window.

Body weight does not appear to significantly alter the clinical effect of the 250 mcg fixed dose across the range of women studied in trials. There is currently no published dose-adjustment guidance based on BMI for Ovidrel, and the available evidence does not support routine dose escalation in higher-weight women. This is an area where the evidence base is thin; the clinical trials for Ovidrel enrolled a relatively narrow body-weight range, and extrapolation to women with BMI above 35 is based on clinical convention rather than direct study. Your REI should discuss this with you if it applies.

Storing Ovidrel Correctly

Correct storage is a patient responsibility that directly affects drug efficacy.

• Refrigerate between 36 and 46 degrees F (2 to 8 degrees C)
• Keep away from the back of the refrigerator where freezing can occur
• Do not freeze. A frozen Ovidrel syringe must be discarded
• Room-temperature storage (up to 77 degrees F / 25 degrees C) is acceptable for up to 30 days if you are traveling or do not have reliable refrigeration during that period
• Store away from light in the original packaging until use
• Do not use past the expiration date on the label

If you are traveling across time zones for retrieval or IUI, pack the syringe in an insulated medication case with a cool pack and carry it in your personal bag rather than checked luggage.

A Note on the Evidence Gap for Women

The clinical trial record for Ovidrel is one area where women's-health research has actually prioritized female subjects, because the drug has no indication in men in this form. The key trials enrolled women undergoing ovarian stimulation, and the 2002 RCT published in Fertility and Sterility directly compared choriogonadotropin alfa to urinary hCG in women undergoing ART, finding no significant difference in oocytes retrieved or clinical pregnancy rate per started cycle.

Where the evidence is thin: outcomes in women with BMI above 35, outcomes in women over age 42 with diminished ovarian reserve, and outcomes in women who have experienced prior OHSS with an hCG trigger and are considering repeat exposure. If you fall into any of these groups, the decision to use Ovidrel vs. A GnRH agonist trigger vs. A modified protocol should be an individualized conversation with your reproductive endocrinologist, not a default decision.

As one ASRM clinical practice committee note states: "The choice of trigger depends on the patient's ovarian response, risk factors, and the protocol used," meaning no single trigger is universally optimal, and shared decision-making between you and your care team is the standard the field endorses.